Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.32 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.31 |
| ▸ | PPARG | P37231 | 2/20 | 0.30 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.30 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.30 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3222543 | 0.87 | NR3C1 (0.34) | SCN9AFPR2MAP3K14NR3C1PGR | |
| SCHEMBL3230779 | 0.80 | PPARG (0.35) | SCN9AGRM2PPARGSLC9A1RXRA | |
| SCHEMBL3213498 | 0.74 | GRM2 (0.48) | CYP3A4GRM2 | |
| SCHEMBL3231611 | 0.74 | SLC9A1 (0.38) | SCN9AGRM2PPARGSLC9A1RXRA | |
| SCHEMBL3261767 | 0.72 | PARP1 (0.37) | GRM2SLC9A1 | |
| SCHEMBL3802310 | 0.72 | SCN9A (0.33) | SCN9AFPR2MAP3K14NR3C1PGR | |
| SCHEMBL3217914 | 0.71 | GRM2 (0.37) | MAPK14SCN9AGRM2PPARGSLC9A1 | |
| SCHEMBL3233045 | 0.69 | PARP1 (0.34) | GRM2SLC9A1 | |
| SCHEMBL3219731 | 0.69 | JAK2 (0.41) | SCN9ACYP3A4 | |
| SCHEMBL3232086 | 0.68 | USP8 (0.35) | GRM2SLC9A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2142516-B1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI SA (FR) | 2012-12-26 | — | — | EP | claimed |
| US-8258130-B2 | Pyrimidine hydrazide compounds as PGDS inhibitors | SANOFI (FR) | 2012-09-04 | — | — | US | claimed |
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2010-02-25 | — | — | US | claimed |
| EP-2142516-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | Sanofi-Aventis (FR) | 2010-01-13 | — | — | EP | claimed |
| WO-2008121670-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2008-10-09 | — | — | WO | claimed |
| EP-2142516-B1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI SA (FR) | 2012-12-26 | — | — | EP | disclosed |
| US-8258130-B2 | Pyrimidine hydrazide compounds as PGDS inhibitors | SANOFI (FR) | 2012-09-04 | — | — | US | disclosed |
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2010-02-25 | — | — | US | disclosed |
| EP-2142516-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | Sanofi-Aventis (FR) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008121670-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | HRH2, HRH1, HRH4 | MAPK14 3894/4885SCN9A 3307/4885FPR2 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.